Obesity confers an increased risk for cardiovascular renal diseases, diabetes mellitus, nonalcoholic steatohepatitis, musculoskeletal disorders, and cancers. Prokineticin‐2 is a peptide hormone, which exists as both a circulating hormone system and a local paracrine‐signaling mechanism within various tissues including the brain, kidney, and adipose. It acts on the G‐protein‐coupled receptors (GPCRs) PKR1 and PKR2. The role of prokineticin‐2 in the central nervous system is the control of food intake. Its anorexigenic effect is at least partly through the hypothalamic melanocortin system. Prokineticin‐2 also prevents adipose tissue expansion by limiting preadipocyte proliferation and differentiation capacity. Prokineticin‐2 signaling is important for insulin capillary passages. It also regulates heart and kidney development and function. Here, we discuss a new obesity peptide prokineticin signaling in central regulation of food intake, adipocyte tissue development, and cardiovascular function. Prokineticin may play a key role in the association between obesity and cardiovascular diseases. We also outline the potential of prokineticin receptor‐1 as target for the treatment of obesity and cardiovascular diseases.
Obesity is a major health problem and an increased risk factor that worsens cardiovascular events leading to higher morbidity and mortality.  Several cardiovascular diseases can also occur due to structural and functional changes of the myocardium through excess fat deposition and other mechanisms related to obesity . However, the mechanisms of relation between obesity and cardiovascular events are unclear. Nevertheless, pharmacological therapy for obesity has great potential to improve cardiovascular problems. Several anorexcigenic peptides have been studied as potential drugs in the treatment of obesity . Recent evidence showed that some brain regions may not only be involved in food intake regulation but also play an important role in the regulation of cardiovascular blood homeostasis . The rising prevalence of both obesity and heart failure make this association an important target for prevention. Therefore, it is important to determine the common mechanisms regulating both obesity and cardiovascular events. Identification of signaling pathways linking obesity and cardiovascular disease is important for the development of novel therapeutics. Here, we summarize the current information on the role of anorexigenic peptide prokineticin in obesity and cardiovascular renal diseases, emphasizing prokineticin receptor‐1 signaling in these events.
2. Prokineticins and their receptors
Prokineticins are anorexigenic and angiogenic hormones. Because of the structural, signaling and functional similarities, prokineticins are considered as cytokines/chemokines . They are released principally by macrophages and reproductive organs . Recently, prokineticin is considered as an adipokine because a high level of prokineticins has been found in obese human WAT . These small peptides (80–120 amino acids) are called prokineticins, because these molecules were first identified as potent contractile factors in the gastrointestinal tract . Two isoforms of prokineticins have been identified: prokineticin‐1 and prokineticin‐2. Prokineticin‐1 has been originally called as endocrine gland‐derived vascular endothelial growth factor (EG‐VEGF),  because of its functional similarity to VEGF. Prokineticin‐2 is also called as Bv8. Both of these peptides are 45% identical with highly conserved N‐terminal AVITGA motif essential for their biological activity [6, 10]. Prokineticin activity is mediated by two G‐protein‐coupled receptors, PKR1 and PKR2 .
2.1. Prokineticin‐2 is an anorexigenic peptide
Circulating hormones and nutrients are integrated to mediate the regulation of short‐term and long‐term dietary intakes in the hypothalamus. A feeding and energy homeostasis control center in the hypothalamus is called as arcuate nucleus (ARC) [12, 13]. The ARC integrates most of the peripheral hormonal signals including leptin, insulin and ghrelin. The ARC has two major subpopulations of primary neurons that express neurohormones with opposing effects on food intake. ARC neurons that release the proopiomelanocortin (POMC)‐derived peptide alpha‐melanocyte‐stimulating hormone (α‐MSH) and cocaine‐ and amphetamine‐regulated transcript (CART) peptide potently reduce food intake [13, 14]. However, neuropeptide Y (NPY)‐producing neurons in the ARC stimulate food intake.
Prokineticin‐2 is involved in the control of food intake and of fat mass through actions in the ARC in the hypothalamus . PKR1 receptor is expressed on both NPY/AgRP and POMC/CART neurons. Intracranial injection of prokineticin‐2 in rats strongly decreases food intake. Controversy, anti‐prokineticin‐2 antibody increases food intake. Anorexigenic effect of prokineticin‐2 is mediated at least partly via the hypothalamic ARC melanocortin system. Prokineticin‐2 increases the release of alpha‐MSH from
Peripheral administration of prokineticin‐2 reduces food intake and body weight in both lean mice and diet‐induced obesity models . This effect of prokineticin‐2 is not evident when appetite is increased or feeding behavior is promoted. Hypothalamic prokineticin‐2 levels were found extremely high in the early neonatal period. However, a decreased level of prokineticin‐2 was evident under fasting conditions . Prokineticin‐2‐knockout mice became obese at the late age. Humans with the inactivating mutations of prokineticin‐2 gene are also obese [17, 19]. The anorectic effects of prokineticin‐2 are abolished by PKR1 antagonists and not observed in mice lacking PKR1 . Thus, the anorectic effects of prokineticin‐2 in the hypothalamus are mediated by PKR1.
2.2. Prokineticin in the development of obesity
The mechanisms underlying the development of obesity include the hypertrophy and/or hyperplasia of adipocytes, adipose tissue (AT) inflammation, impaired extracellular matrix remodeling and fibrosis together with an altered secretion of adipokines . AT expansion involves two distinct mechanisms: an enlargement in adipose cells and an increase of adipocytes number . Differentiated adipocytes are post‐mitotic and therefore hyperplasia is the result of increased
Prokineticin‐2 levels were found to be high in obese human WAT . Prokineticin‐2 suppresses AT expansion by two distinct mechanisms: the central regulation of food intake and limiting preadipocyte proliferation and differentiation. The central regulation of body weight is counteracted by loss of PKR1 in adipose tissue in mice. Indeed, an abnormally excessive abdominal fat mass accumulation was observed in these mice where the PKR1 specifically deleted in the adipocytes (PKR1
2.3. Prokineticin in insulin resistance
The endothelium is essential for insulin transcapillary delivery to the skeletal muscle interstitium. This process is the rate‐limiting step in insulin‐stimulated glucose uptake.  The impairment of insulin delivery process contributes to insulin resistance . On the other hand, insulin resistance leads to endothelial dysfunction . Thus, the vascular endothelium is a potential therapeutic target for the prevention of insulin resistance and related complications .
Endothelium‐specific PKR1‐knockout mice (PKR1ec
As a summary, prokineticin regulates appetite (effects in central nervous system (CNS)) and suppresses adipocyte expansion (direct effect on adipocyte tissue), promotes normal fat storage (endothelial‐dependent effect) and increases insulin sensitivity. Therapeutic strategies targeting PKR1 could be important to treat obesity and obesity‐associated insulin resistance.
2.4. Prokineticin in cardiovascular regulation
Obesity is both an independent risk factor and a risk marker for the development of asymptomatic and symptomatic coronary artery disease, heart failure and atrial fibrillation . The relationship between obesity and cardiovascular diseases may be associated with hemodynamic and anatomic cardiovascular changes related to excess body mass . However, the relationship can also be mediated by obesity‐related metabolic, inflammatory and neurohormonal changes.
Altered expression of prokineticins and their receptors has been implicated in the development of a number of pathological cardiac conditions, including heart failure . Prokineticins and their receptors have been identified as an important cardiovascular‐signaling system especially cardiac cell commitment and cell‐to‐cell communications .
PKR1‐mediated signaling contributes to cardiomyocyte survival and adult heart repair. PKR1 activates Akt in cardiomyocyte to protect these cells against hypoxia‐mediated apoptosis . Transgenic (TG) mice‐overexpressing PKR1 in the cardiomyocytes (TG‐PKR1) had an increased number of epicardial‐derived progenitor cells (EPDCs), with an increase of capillary density and coronary arterioles.  The cardiac‐PKR1 signaling up‐regulates its own ligand prokineticin‐2 to stimulate the EPDC differentiation into endothelial and smooth muscle cells to promote neovasculogenesis . However, cardiomyocyte‐PKR1 is essential for cardiomyocyte survival and contractility. PKR1null mice displayed cardiomyocyte‐contractile defects and apoptosis partially due to lack of PKR1 signaling in cardiomyocytes. 
In endothelial cells (ECs), PKR1 activates Akt and MAPK to promote proliferation, migration and angiogenesis. In agreement with the
There was significantly less capillary formation in adult PKR1ec-/- hearts. The posterior walls of PKR1ec‐/‐ hearts were thinner, which was due to the loss of capillary formation and a high level of apoptosis . The remaining viable heart muscle is subject to greater biomechanical stress, triggering hypertrophy . Shortening fractions (indicators of left ventricular contractility) were progressively reduced in mutant mice. PKR1ec-/- hearts displayed EC deregulation, capillary refraction, apoptosis, fibrosis and ectopic lipid deposition, abnormal insulin signaling in hearts resulting in impaired diastolic function.
The ECs of hearts exhibited severely decreased FICT‐insulin uptake, indicating defective
PKR1 signaling also contributes to heart development. In developing heart, PKR1 regulates epicardial‐mesenchymal transition (EMT) to form epicardial‐derived progenitor cell (EPDC) . Genetic ablation of PKR1 in epicardium leads to ventricular hypoplasia and septal defects during embryogenesis. Impaired vasculogenesis in these mice is due to impaired EPDC proliferation as well as a defective EPDC differentiation into endothelial and smooth muscle cell type. PKR1 in EPDCS activates Akt signaling, changes cell morphology, actin cytoskeleton remodeling and EMT gene expression profile. Epicardial‐PKR1 contributes to cardiomyocyte, proliferation and rhythmicity in a paracrine pathway.
2.5. Prokineticin in renal development and function
Global PKR1‐knockout mice have peripheral obesity accompanied by a diabetes‐like syndrome at the late ages (36 weeks old) , mainly due to endothelial dysfunction and impaired adipose tissue functions . These mice also exhibited cardiomegaly, severe interstitial fibrosis and cardiac dysfunction under the stress conditions. These mice also displayed impaired renal tubular dilation, reduced glomerular capillaries, urinary phosphate excretion and proteinuria .
Similarly, endothelial‐specific PKR1‐knockout mice (PKR1ec-/-) also displayed dilatation of Bowman's spaces in most glomeruli, a compact glomerulus, fibrosis and enlarged tubular structures with a swollen necrotic nucleus, abnormal mitochondria and aberrant organization of podocytes. Abnormal tubular function with higher levels of absolute renal phosphate (Pi) excretion in the PKR1ec-/- mice is due to lower levels of sodium‐calcium and sodium phosphate exchanger. The morphological changes in the PKR1ec-/- kidneys were associated with higher levels of apoptosis and impaired insulin signaling and lipid accumulation. Mutant mice displayed high levels of creatinine clearance and proteinuria.  Endothelial dysfunction resulted from loss of PKR1 signaling partially underlies the pathological features of heart and kidney.
PKR1 signaling in kidney is essential for nephron development during embryogenesis . Recently, it has been shown that mutant mice with targeted PKR1 gene disruptions in nephron progenitors exhibited partial embryonic and postnatal lethality due to hypoplastic kidneys with premature glomeruli and necrotic nephrons. Kidney developmental defects in these mice are manifested in the adult stage as renal atrophy with glomerular defects, nephropathy and uremia. Thus, PKR1 is necessary for renal mesenchymal‐epithelial transition (MET) that is involved in the formation of renal progenitors, regulating glomerulogenesis toward forming nephrons during kidney development. Indeed, PKR1 through NFATc3 modifies MET processing to the development of nephron.
PKR1 signaling has various beneficial effects, e.g., central regulation of appetite, the suppression of adipocyte mass and insulin‐sensitizing effects on skeletal muscle and other tissues, cardiac regenerative effects and regulation of kidney function. This has attracted considerable interest in the possible use of this receptor as a target for treatments combating obesity, diabetes and cardiovascular diseases. Intracardiac PKR1 gene transfer improved survival rate and heart functions after myocardial infarction . Since PKR2 has been found to contribute to vascular leakage and hypertrophic cardiomyopathy , several laboratories are focused on the discovery of PKR1 agonist. Recently, PKR1 non‐peptide agonist has been identified . PKR1 agonist prevents cardiac lesion formation and improved cardiac function after myocardial infarction in mice, promoting proliferation of cardiac progenitor cells and neovasculogenesis
How prokineticin‐2 contributes to the AT remodeling , how it modulates the interaction between the adipocytes, macrophages and endothelial cells to regulate AT expansion  remains also to be determined. Circulating prokineticin levels in obese, diabetic and heart failure patients remain to be explored.
I wish to thank people involved in the studies described here, including Kyoji Urayama, Célia Guilini, Gulen Turkeri, Monia Boulberdaa, Mojdeh Dormishian, Rehana Qureshi, Himanshu Arora and Adeline Gasser. The publication was supported in part by grants from Fondation pour la Recherche Médicale (Equipe Labellisée), Centre National de la Recherche Scientifique and Université de Strasbourg. This work has also been published within the LABEX ANR‐10‐LABX‐ 0034_Medalis and received a financial support from the French government managed by Agence Nationale de la Recherche (ANR) under “Programme d׳investissement d׳avenir.”